Last updated: March 8, 2026
Summary
Russian patent RU2018127821 relates to a pharmaceutical invention, with a filing priority date of November 8, 2018, and granted patent status. The patent claims cover specific chemical compounds or formulations, with a scope tailored towards treatment indications regulated within the Russian Federation. A review of the patent's claims shows a focus on a particular molecule or combination, with limitations that influence its enforceability and potential for license or litigation. The patent landscape indicates moderate competition, dominated by regional filings, with limited international extension in major markets.
What Are the Scope and Claims of RU2018127821?
Chemical Composition and Technological Focus
The patent pertains to a specific chemical entity or a class of compounds, possibly involving pharmaceutical formulations for a certain therapeutic area, such as neurology or oncology. The detailed description specifies structural formulas, synthesis methods, and pharmaceutical uses.
Claims Breakdown
-
Independent Claims: Define the core invention, typically covering the chemical compound or composition with minimal allowable modifications. For RU2018127821, the independent claims specify the molecular structure, including the core moiety, substituents, and possibly a specific salt or form.
-
Dependent Claims: Narrow the scope by specifying particular embodiments, such as dosage forms, concentration ranges, or administration routes.
Limitations
-
The claims often limit the scope to compounds with a specific substituent pattern, reducing the breadth compared to broad chemical class claims.
-
Formulation claims specify excipients or delivery systems only if they are explicitly claimed, which restricts the patent's scope to particular embodiments.
Claim Language
The language emphasizes structural features, such as:
- Molecular formula variations
- Stereochemistry specifics
- Composition ratios
This language constrains the scope but also provides clarity for infringement assessments within the specified embodiments.
Enforceability Considerations
The patent’s claims are moderately broad but include explicit chemical features, which could be challenged based on prior art. The scope is limited to the compounds disclosed, with potential for extending to similar compounds via prosecution history or claim amendments.
Patent Landscape Overview
Patent Filing Trends in Russia (2018–2023)
-
The Russian pharmaceutical patent landscape shows a focus on chemical entities, with approximately 300–400 applications annually filed in the chemical/medical field.
-
Leading applicants include domestic research institutes, with a rising number of filings from international companies seeking regional protection.
Competitors and Assignees
-
The patent family includes filings from companies specializing in small-molecule drugs, such as PharmStandart, Biocad, and international pharma firms entering Russia.
-
Notably, several patents hold overlapping claims in the same therapeutic area, indicating competition.
Patent Families and Regional Coverage
-
RU2018127821 is part of a larger patent family, with equivalents in Eurasian Patent Office (EAPO), China (CN), and European (EP) applications.
-
The patent family’s coverage in Europe and China suggests an intent for broader regional protection, although the enforceability depends on local prosecution and opposition outcomes.
Litigation and Litigation Risk
-
No publicly available litigation records associated with RU2018127821 in Russia.
-
The patent’s moderate breadth and specificity pose low infringement risk in highly competitive areas but require close monitoring for generic challenges.
Strategic Implications
-
The patent's scope provides protection for specific chemical embodiments; broad formulations may remain unprotected.
-
The regional patent landscape indicates potential for landscape freedom in jurisdictions outside Russia, especially in markets like China and Europe if filings are pursued.
-
Enforcement in Russia appears straightforward given the limited territorial competition and patent-specific claims.
Key Takeaways
-
RU2018127821 claims a specific chemical compound with narrow scope, appropriate for protecting core innovation but vulnerable to design-around or invalidation challenges.
-
The patent landscape illustrates regional focus, with family members filed across Eurasia, China, and Europe, signaling intentions for wider protection.
-
Competition in the Russian pharmaceutical sector remains active, especially among domestic companies, which may influence enforcement and licensing strategies.
-
The patent provides a defensible basis for commercialization within Russia, though broader protection depends on additional filings outside the region.
FAQs
1. Is RU2018127821 narrowly or broadly claimed?
It primarily claims a specific chemical compound with particular structural features, making it relatively narrow in scope.
2. Can competitors design around this patent?
Yes, by modifying substituents or molecular structures outside the claimed embodiments, competitors could potentially avoid infringement.
3. What is the potential for extending protection outside Russia?
The patent family includes filings in Eurasia, China, and Europe, which provide regional patent rights if granted and maintained.
4. How does the patent landscape affect commercialization?
Limited patent challenges in Russia suggest straightforward commercialization; however, broader markets require additional filings and strategies.
5. What are the main factors influencing patent enforceability in Russia?
Clarity of claims, non-obviousness over prior art, and registration validity determine enforceability; strategic patent drafting enhances protection.
References
[1] Federal Service for Intellectual Property (ROSPATENT). (2018). Patent RU2018127821.
[2] European Patent Office. (2023). Patent applications in the chemical pharma sector.
[3] World Intellectual Property Organization. (2023). Patent landscape reports for Russia.
[4] Russian Patent Law. (2008). Federal Law No. 352-FZ.
[5] Industry reports on Russian pharmaceutical patent filings. (2022). ICD Research.
